Table 2.
Clinical data of patients included in the analysis (no variables were significantly different between the 2 groups).
| Demographics | Controls (n=9) | Cases (n=17) | P value | ||||
| Age (years), mean (SD) | 49 (12.4) | 54 (8.2) | .96 | ||||
| Race, n (%) |
|
|
.66 | ||||
|
|
White | 8 (89) | 14 (82) |
|
|||
|
|
Other | 1 (11) | 3 (18) |
|
|||
| Height (m), mean (SD) | 1.78 (0.14) | 1.70 (0.10) | .81 | ||||
| Weight (kg), mean (SD) | 83.1 (23.6) | 75.3 (16.6) | .27 | ||||
| Cancer type, n (%) |
|
|
.59a | ||||
|
|
Breast | 4 (44) | 5 (29) |
|
|||
|
|
Ovarian | 0 (0) | 2 (12) |
|
|||
|
|
Lung | 0 (0) | 1 (6) |
|
|||
|
|
Colorectal | 2 (22) | 6 (35) |
|
|||
|
|
Otherb | 4 (44) | 8 (47) |
|
|||
| Neurotoxic chemotherapy agent , n (%) |
|
|
.60 | ||||
|
|
Taxane | 5 (56) | 6 (35) |
|
|||
|
|
Platinum | 2 (22) | 5 (29) |
|
|||
|
|
Taxane and platinum | 2 (22) | 6 (35) |
|
|||
| Time since treatment completion (months), mean (SD) | 8.27 (16.7) | 2.53 (2.70) | .08 | ||||
aChi-square test between chemotherapy-induced peripheral neuropathy cases and controls that had breast cancer, ovarian cancer, lung cancer, or colorectal cancer versus only other cancer types.
bOther cancer types include liver cancer, esophageal cancer, prostate cancer, cervical cancer, and pancreatic cancer.